Németh, Krisztina
Tóth, Blanka
Sarnyai, Farkas
Koncz, Anna
Lenzinger, Dorina
Kereszturi, Éva
Visnovitz, Tamás
Kestecher, Brachyahu Meir
Osteikoetxea, Xabier
Csala, Miklós
Buzás, Edit I.
Tamási, Viola
Funding for this research was provided by:
National Cardiovascular Laboratory Program (RRF-2.3.1-21-2022-00003, RRF-2.3.1-21-2022-00003, RRF-2.3.1-21-2022-00003, RRF-2.3.1-21-2022-00003, RRF-2.3.1-21-2022-00003, RRF-2.3.1-21-2022-00003, RRF-2.3.1-21-2022-00003)
Hungarian National Research, Development and Innovation Office (2019-2.1.7-ERA-NET-2021-00015, FK138115, FK138115, 2019-2.1.7-ERA-NET-2021-00015, 2019-2.1.7-ERA-NET-2021-00015, FK138115, 2019-2.1.7-ERA-NET-2021-00015, 2019-2.1.7-ERA-NET-2021-00015, 2019-2.1.7-ERA-NET-2021-00015, FK138115, 2019-2.1.7-ERA-NET-2021-00015, FK138115)
Higher Education Excellence Program (FIKP), Therapeutic Thematic Programme
Horizon 2020 (739593, 739593, 739593, 739593, 739593, 739593, 739593)
ELKH SE Translational Extracellular Vesicle Research Group
INKUBÁTOR program of the Department of Molecular Biology, Semmelweis University, Budapest
Semmelweis University
Article History
Received: 12 December 2022
Accepted: 17 March 2023
First Online: 31 March 2023
Declarations
:
: All animal experiments followed the European Union’s Council Directive (86/609/EEC) and were approved by the Semmelweis University’s Institutional Animal Care and Use Commitee (PE/EA/1655-7/2018).
: Not applicable.
: EIB is member of the Advisory Board of Sphere Gene Therapeutics Inc. (Boston, MA, US). XO was a salaried employee of AstraZeneca and had stocks in AstraZeneca.